Colifin is a small molecule commercialized by Spexis, with a leading Phase II program in Lung Infections. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Colifin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Colifin is expected to reach an annual total of $143 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Colistimethate sodium is under development for the treatment of lung infections associated with cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic Pseudomonas aeruginosa (PA) and non-cystic fibrosis bronchiectasis (NCFBE). it is administered through inhalational route. It targets bacterial cell membrane.
Spexis formerly Polyphor Ltd, is a biopharmaceutical company developing immuno-oncology medicines and antibiotics for treatment of cancer and respiratory diseases. The company’s lead product candidate includes balixafortide (POL6326) an antagonist chemokine receptor CXCR4 for treatment of metastatic breast cancer; inhaled murepavadin a novel class outer membrane protein targeting antibiotic (OMPTA) to treat pseudomonas aeruginosa in cystic fibrosis; POL6014 an inhaled inhibitor of neutrophil elastase for the treatment of cystic fibrosis and other severe lung diseases. It has also discovered POL7306 a novel class of antibiotics the outer membrane protein targeting antibiotics (OMPTA) to treat infections caused by gram-negative bacteria including mdr strains. The company in collaboration with the University of Zurich has established a proprietary macrocycle-based discovery platform for development of pipeline products. Spexis is headquartered in Allschwil, Switzerland.
The operating loss of the company was CHF4.3 million in FY2021, compared to an operating loss of CHF42.4 million in FY2020. The net loss of the company was CHF11.9 million in FY2021, compared to a net loss of CHF45 million in FY2020.
For a complete picture of Colifin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.